Literature DB >> 8245720

Localization of a liver-specific enhancer in the apolipoprotein E/C-I/C-II gene locus.

N S Shachter1, Y Zhu, A Walsh, J L Breslow, J D Smith.   

Abstract

The sequences necessary for liver-specific expression of the apolipoprotein (apo) E gene have been shown to reside 3' to the gene, within the apoE/C-I/C-II gene cluster, but have not been precisely characterized. Utilizing a transient transfection reporter gene assay based on the apoC-II promoter, we have localized a liver-specific enhancer to its approximate limit dimension of 154 base pairs. This enhancer directed liver-specific expression of an apoE gene construction in transgenic mice. A DNaseI protection assay revealed two footprints over an inverted repeat of a known transcriptionally active motif, TGACCT. DNaseI-sensitive sites were present in three of six repeats of a motif (consensus GCAAACA) which has been postulated to represent the recognition sequence of a hepatic transcriptional activity, HNF-5. This region of DNA may function as a liver-specific enhancer for the entire apoE/C-I/C-II gene cluster.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8245720

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  9 in total

1.  Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.

Authors:  N S Shachter; T Ebara; R Ramakrishnan; G Steiner; J L Breslow; H N Ginsberg; J D Smith
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Comparative genomic analysis reveals a distant liver enhancer upstream of the COUP-TFII gene.

Authors:  Nadine Baroukh; Nadav Ahituv; Jessie Chang; Malak Shoukry; Veena Afzal; Edward M Rubin; Len A Pennacchio
Journal:  Mamm Genome       Date:  2005-02       Impact factor: 2.957

3.  Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association.

Authors:  Chang-En Yu; Howard Seltman; Elaine R Peskind; Nichole Galloway; Peter X Zhou; Elisabeth Rosenthal; Ellen M Wijsman; Debby W Tsuang; Bernie Devlin; Gerard D Schellenberg
Journal:  Genomics       Date:  2007-04-16       Impact factor: 5.736

4.  Expression liver-directed genes by employing synthetic transcriptional control units.

Authors:  Marie-Luise Lemken; Wolfgang-A Wybranietz; Ulrike Schmidt; Florian Graepler; Sorin Armeanu; Michael Bitzer; Ulrich-M Lauer
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

5.  Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1.

Authors:  M C Jong; M J Gijbels; V E Dahlmans; P J Gorp; S J Koopman; M Ponec; M H Hofker; L M Havekes
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

6.  Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice.

Authors:  N S Shachter; T Hayek; T Leff; J D Smith; D W Rosenberg; A Walsh; R Ramakrishnan; I J Goldberg; H N Ginsberg; J L Breslow
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

Review 7.  Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.

Authors:  Anna Wolska; Richard L Dunbar; Lita A Freeman; Masako Ueda; Marcelo J Amar; Denis O Sviridov; Alan T Remaley
Journal:  Atherosclerosis       Date:  2017-10-20       Impact factor: 5.162

8.  Discovery and characterization of human exonic transcriptional regulatory elements.

Authors:  Arshad H Khan; Andy Lin; Desmond J Smith
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

9.  Apolipoprotein E-C1-C4-C2 gene cluster region and inter-individual variation in plasma lipoprotein levels: a comprehensive genetic association study in two ethnic groups.

Authors:  Dilek Pirim; Zaheda H Radwan; Xingbin Wang; Vipavee Niemsiri; John E Hokanson; Richard F Hamman; Eleanor Feingold; Clareann H Bunker; F Yesim Demirci; M Ilyas Kamboh
Journal:  PLoS One       Date:  2019-03-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.